Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | CD44 | P16070 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30818918 | 1.00 | SLC9A1 (0.44) | SLC9A1GAAABL1CD44SMN1; SMN2 | |
| SCHEMBL10744416 | 0.89 | GAA (0.52) | SLC9A1GAAABL1CD44SMN1; SMN2 | |
| SCHEMBL30515968 | 0.85 | CD44 (0.56) | SLC9A1GAAABL1CD44SMN1; SMN2 | |
| SCHEMBL17030863 | 0.85 | CD44 (0.56) | SLC9A1GAAABL1CD44SMN1; SMN2 | |
| SCHEMBL16636823 | 0.84 | SLC9A1 (0.40) | SLC9A1GAAABL1SMN1; SMN2CYP3A4 | |
| SCHEMBL16637172 | 0.84 | CFTR (0.38) | SLC9A1GAAABL1CD44SMN1; SMN2 | |
| SCHEMBL21232254 | 0.84 | FADS1 (0.42) | SLC9A1GAAABL1CD44SMN1; SMN2 | |
| SCHEMBL30390446 | 0.84 | SLC9A1 (0.40) | SLC9A1GAAABL1SMN1; SMN2CYP3A4 | |
| SCHEMBL24010000 | 0.81 | GAA (0.58) | GAASMN1; SMN2CYP3A4ALDH1A1KDM4E | |
| SCHEMBL10742310 | 0.81 | ABL1 (0.34) | SLC9A1GAAABL1CD44SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166624-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2024-05-23 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| EP-4301734-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | Flare Therapeutics Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023278816-A1 | HETEROCYCLIC ALDEHYDE TRAPPING COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022187203-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS, INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| US-7348332-B2 | (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines | HOFFMANN-LA ROCHSE INC. (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1871748-A1 | (3,4-DIHYDRO-QUINAZOLIN-2-YL)-INDAN-1-YL-AMINES | F. Hoffmann-Roche AG (CH) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006108773-A1 | (3,4-DIHYDRO-QUINAZOLIN-2-YL)-INDAN-1-YL-AMINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | WO | disclosed |
| US-20060229323-A1 | (3,4-Dihydro-quinazolin-2-yl)-indan-1-yl-amines | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | US | disclosed |
| EP-0760819-B1 | TRICYCLIC DICARBONYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2000-07-19 | — | — | EP | disclosed |
| CN-1044245-C | Tricyclic Dicarbonyl derivatives | HAFFMANN LA ROCHE AG F (DE) | 1999-07-21 | — | — | CN | disclosed |
| US-5688803-A | BRAIN DISORDERS; PSYCHOLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1997-11-18 | — | — | US | disclosed |
| CN-1149295-A | Tricyclic Dicarbonyl derivatives | HOFFMANN LA ROCHE (CH) | 1997-05-07 | — | — | CN | disclosed |
| EP-0760819-A1 | TRICYCLIC DICARBONYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-12 | — | — | EP | disclosed |
| WO-1995032205-A1 | TRICYCLIC DICARBONYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1995-11-30 | — | — | WO | disclosed |
| US-4379929-A | BACTERIOSTATS | ELI LILLY AND COMPANY (US) | 1983-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166624-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | SLC9A1 2107/4885GAA 2448/4885ABL1 3094/4885 |
| US-20060229323-A1 | (3,4-Dihydro-quinazolin-2-yl)-indan-1-yl-amines | HTR5A, HTR1A, HTR1E | SLC9A1 517/4885GAA 2472/4885ABL1 542/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | SLC9A1 2755/4885GAA 27/4885ABL1 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.